Tuesday, May 14, 2013

• Alexza Reports 2013 First Quarter Financial ResultsPR Newswire( (Tue, May 14)

Wednesday, May 8, 2013

• Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S.PR Newswire( (Wed, May 8)
• Teva and Alexza Announce Teva’s License to Market ADASUVE® in the U.S.Business Wire( (Wed, May 8)
• Teva and Alexza Announce Teva's License to Market ADASUVE® in the U.S.PR Newswire( (Wed, May 8)

Monday, May 6, 2013

• Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of EpilepsyPR Newswire( (Mon, May 6)

Wednesday, May 1, 2013

• Update: Alexza to Report 2013 First Quarter Financial Results on Tuesday, May 14, 2013PR Newswire( (Wed, May 1)

Monday, April 22, 2013

• Alexza to Report 2013 First Quarter Financial Results on Thursday, May 9, 2013PR Newswire( (Mon, Apr 22)

Tuesday, March 26, 2013

• Alexza Reports 2012 Fourth Quarter and Full Year Financial ResultsPR Newswire( (Tue, Mar 26)

Wednesday, March 13, 2013

• Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial OfficerPR Newswire( (Wed, Mar 13)

Wednesday, March 6, 2013

• Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013PR Newswire( (Wed, Mar 6)

Monday, February 25, 2013

• Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming Investor ConferencesPR Newswire( (Mon, Feb 25)

Thursday, February 21, 2013

• Alexza Receives Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European UnionPR Newswire( (Thu, Feb 21)

Thursday, February 14, 2013

• Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's SuccessMarketwired( (Thu, Feb 14)